The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Atacicept, Mavrilimumab Drug Updates, Trials, Safety Data

Atacicept, Mavrilimumab Drug Updates, Trials, Safety Data

September 1, 2014 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

You Might Also Like
  • Rheumatology Drug Updates, Trials, Safety Data
  • Rheumatology Drug Updates, Trials, Safety Data
  • Rheumatology Drug Updates, Trials, Safety Data
Explore This Issue
September 2014
Also By This Author
  • 14 Rheumatology Treatments Make Top 50 List of Drugs That Can Cause Anaphylaxis

Atacicept failed to improve flare rate or time to first flare in patients with systemic lupus erythematosus (SLE).1 Atacicept is a fusion protein containing the extracellular, ligand-binding portion of the TACI (transmembrane activator and calcium-modulator and cyclophilin-ligand [CAML]-interactor) receptor, and a modified Fc portion of human IgG that blocks BLyS (similar to belimumab). It also contains a B-cell activating factor (a proliferation-inducing ligand [APRIL]). Levels of both APRIL and BlyS are increased in SLE patients, suggesting that blocking both would be more beneficial than blocking either one alone. The agent would also block both plasma and B cells.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

This study was a randomized, double-blind, placebo-controlled, Phase 2/3 study in patients with moderate-to-severe SLE. Patients received subcutaneous (SC), twice weekly atacicept 75 mg, atacicept 150 mg or placebo, for four weeks, followed by weekly injections for 48 weeks. The primary outcome measure was the proportion of patients obtaining at least one disease flare during the 52-week trial. The main secondary endpoint was the time to the first flare. The disease flare rate among patients (n=461) treated with 75 mg of atacicept twice weekly was 58% at Week 52. The placebo rate was 54%. The atacicept 150 mg arm was prematurely discontinued due to two deaths. Analysis of the 150 mg atacicept-treated patients suggested a beneficial effect vs. placebo in time to first flare, and flare rates. Both doses of atacicept were associated with decreased total IgG levels, decreased anti-double-stranded DNA (anti-dsDNA) antibody levels and increases in C3 and C4 levels. IgG levels decreased by 30% in the 75 mg atacicept-treated group and by 38% in the 150 mg atacicept-treated group (placebo increased by 3%). Anti-dsDNA also decreased by 31% and 38%, respectively, in the active treatment groups (placebo-treated patients increased by 14%).

Treatment-emergent adverse events were mild to moderate, including upper respiratory infection (17%), urinary tract infection (14%) and headache (16%). The serious infections noted in this study were similar to those seen in both the rituximab and belimumab SLE trials, and the rheumatoid arthritis (RA) atacicept trials. Neither of the two deaths was attributed to study medication.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Mavrilimumab, currently in Phase 2b, is a human monoclonal antibody targeting the alpha subunit of the granulocyte macrophage colony-stimulating factor receptor, which inhibits the mononuclear phagocyte pathway.2 The Phase 2a EARTH study confirmed the efficacy of this agent using ACR20 response, with RA patients showing a rapid clinical response.3 This was a randomized, double-blind, placebo-controlled study in patients (n=239) with moderately active, adult-onset RA, with disease activity score (DAS28-CRP) ≥3.2 for at least a three-month duration despite methotrexate (MTX; dose 7.5–25 mg/week), and positive anticyclic citrullinated peptide antibody >5 IU/mL and/or rheumatoid factor >14 IU/mL. Patients were randomized to receive SC injections every other week of 10, 30, 50 or 100 mg of mavrilimumab or placebo for 12 weeks.

Pages: 1 2 3 | Single Page

Filed Under: Biologics & Biosimilars, Conditions, Drug Updates, Rheumatoid Arthritis, Safety, SLE (Lupus) Tagged With: atacicept, Biologics, drug, Kaufman, mavrilimumab, Research, Rheumatoid arthritis, rheumatologist, rheumatology, rituximab, Safety, Systemic lupus erythematosusIssue: September 2014

You Might Also Like:
  • Rheumatology Drug Updates, Trials, Safety Data
  • Rheumatology Drug Updates, Trials, Safety Data
  • Rheumatology Drug Updates, Trials, Safety Data
  • Rheumatology Drug Updates, Trials, Safety Data

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)